Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Defining high-risk prostate cancer.

Goldberg H, Baniel J, Yossepowitch O.

Curr Opin Urol. 2013 Jul;23(4):337-41. doi: 10.1097/MOU.0b013e328361dba6. Review.

PMID:
23665740
[PubMed - indexed for MEDLINE]
2.

Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.

Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA.

J Urol. 2007 Aug;178(2):493-9; discussion 499. Epub 2007 Jun 11.

PMID:
17561152
[PubMed - indexed for MEDLINE]
3.

Evaluating localized prostate cancer and identifying candidates for focal therapy.

Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll PR, Rubin MA, Scardino PT.

Urology. 2008 Dec;72(6 Suppl):S12-24. doi: 10.1016/j.urology.2008.10.004.

PMID:
19095124
[PubMed - indexed for MEDLINE]
4.

The epidemiology of high-risk prostate cancer.

Punnen S, Cooperberg MR.

Curr Opin Urol. 2013 Jul;23(4):331-6. doi: 10.1097/MOU.0b013e328361d48e. Review.

PMID:
23619582
[PubMed - indexed for MEDLINE]
5.

Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.

Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, Vergunst H, Sedelaar JP, Fütterer JJ, Barentsz JO.

Eur Urol. 2012 Nov;62(5):902-9. doi: 10.1016/j.eururo.2012.01.047. Epub 2012 Feb 1.

PMID:
22325447
[PubMed - indexed for MEDLINE]
6.

Role of percent positive biopsies and endorectal coil MRI in predicting prognosis in intermediate-risk prostate cancer patients.

D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A.

Cancer J Sci Am. 1996 Nov-Dec;2(6):343-50.

PMID:
9166555
[PubMed - indexed for MEDLINE]
7.

An evidence review of active surveillance in men with localized prostate cancer.

Ip S, Dahabreh IJ, Chung M, Yu WW, Balk EM, Iovin RC, Mathew P, Luongo T, Dvorak T, Lau J.

Evid Rep Technol Assess (Full Rep). 2011 Dec;(204):1-341. Review.

PMID:
23126653
[PubMed - indexed for MEDLINE]
Free Article
8.

Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.

Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J.

Eur Urol. 2013 Jan;63(1):101-7. doi: 10.1016/j.eururo.2012.08.066. Epub 2012 Sep 5.

PMID:
22980443
[PubMed - indexed for MEDLINE]
10.

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.

Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I.

J Urol. 2007 Feb;177(2):540-5. Review.

PMID:
17222629
[PubMed - indexed for MEDLINE]
11.

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H.

Eur Urol. 2011 Nov;60(5):1045-54. doi: 10.1016/j.eururo.2011.08.003. Epub 2011 Aug 25. Review.

PMID:
21871709
[PubMed - indexed for MEDLINE]
12.

Pretreatment prostate-specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer.

Roach M 3rd, Chen A, Song J, Diaz A, Presti J Jr, Carroll P.

Semin Urol Oncol. 2000 May;18(2):108-14.

PMID:
10875450
[PubMed - indexed for MEDLINE]
13.

Point: Impact of prostate-specific antigen velocity on management decisions and recommendations.

Loeb S, Carter HB.

J Natl Compr Canc Netw. 2013 Mar 1;11(3):281-5.

PMID:
23486454
[PubMed - indexed for MEDLINE]
14.

Prostate cancer nomograms: a review of their use in cancer detection and treatment.

Caras RJ, Sterbis JR.

Curr Urol Rep. 2014 Mar;15(3):391. doi: 10.1007/s11934-013-0391-0. Review.

PMID:
24452739
[PubMed - indexed for MEDLINE]
15.

The contemporary concept of significant versus insignificant prostate cancer.

Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH.

Eur Urol. 2011 Aug;60(2):291-303. doi: 10.1016/j.eururo.2011.05.006. Epub 2011 May 17. Review.

PMID:
21601982
[PubMed - indexed for MEDLINE]
16.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.

Mayo Clin Proc. 2001 Jun;76(6):576-81.

PMID:
11393495
[PubMed - indexed for MEDLINE]
17.

Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.

Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S, Conrad S, Henke R, Huland E, Huland H.

Eur Urol. 1999;36(1):21-30.

PMID:
10364651
[PubMed - indexed for MEDLINE]
18.

Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease.

Reese AC, Cooperberg MR, Carroll PR.

J Urol. 2010 Jul;184(1):114-9. doi: 10.1016/j.juro.2010.03.025. Epub 2010 May 15.

PMID:
20478578
[PubMed - indexed for MEDLINE]
19.

Future prospects: who is the patient who still dies of prostate cancer following local treatment of high-risk prostate cancer? Can we prolong their lives using modern treatment approaches?

Ayres BE, Sooriakumaran P.

Curr Opin Urol. 2013 Jul;23(4):372-6. doi: 10.1097/MOU.0b013e328361ebea. Review.

PMID:
23665741
[PubMed - indexed for MEDLINE]
20.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

PMID:
20883488
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk